Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT07010432
Recruiting Phase 1

The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

NCT07010432 · tracked via the Priya Life Science Denmark tracker
Sponsor
Novo Nordisk A/S
Phase
Phase 1
Started
2025-06-12
Last updated
2026-09-10

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

Cagrilintide →Semaglutide →Placebo cagrilintidePlacebo semaglutide

Cagrilintide: Participants will receive once-weekly cagrilintide subcutaneously.

Semaglutide: Participants will receive once-weekly semaglutide subcutaneously.

Placebo cagrilintide: Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.

Placebo semaglutide: Participants will receive once-weekly placebo matched to semaglutide subcutaneously.

Study summary

In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagrilintide can reduce the decline in bone mass associated to weight loss. Participants will either get cagrilintide, semaglutide, CagriSema (cagrilintide combined with semaglutide) or placebo. Which treatment participants get is decided by chance. Semaglutide is already approved for the treatment of overweight and obesity and can be prescribed by doctors. Cagrilintide and CagriSema are new medications currently under development for weight management. The study will last for about 79 weeks.

Eligibility

Sex
FEMALE
Min age
50 Years
Max age
70 Years
Healthy volunteers
No
Inclusion criteria * Female. * Post-menopausal at screening (defined as minimum 12 months of amenorrhea, high levels of follicular stimulating hormone (FSH) 16 - 130 international units per liter (IU/L), and low levels of anti-müllerian hormone (AMH) and inhibin B). * Age 50-70 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) greater than or equal to \>= 30.0 kilograms per square meter (kg/m\^2). Exclusion criteria * Previous or current bone disease (e.g., osteoporosis, Paget's disease of bone, or bone cancer). * Presence of disease affecting bone metabolism (e.g., diabetes mellitus, hyperparathyroidism, hyper or hypothyroidism, chronic kidney disease, celiac disease, or inflammatory diseases (e.g., psoriatic arthritis or ankylosing spondylitis)). * Treatment with any medication affecting bone metabolism within 6 months prior to screening as judged by the investigator (e.g., anti-resorptive medication, anabolic medication, systemic hormone replacement therapy (HRT), or systemic corticosteroids).

Primary outcome measure(s)

  • Relative change in volumetric bone mineral density (vBMD) of the total hip assessed by quantitative computed tomography (QCT) — From baseline to end of treatment (week 68)
    Measured in percentage (%).

Trial sites (1)

FacilityCityRegionStatus
Steno Diabetes Center Copenhagen Herlev Denmark Recruiting

On this site

📄 Ozempic (semaglutide) drug profile →

More Novo Nordisk A/S trials in Denmark

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) Active, not recruiting
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight Active, not recruiting
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity Recruiting
A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN Enrolling by invitation

Other trials for the same condition

Inflammation's Impact on Heart Disease and Diabetes Recruiting
WIN: a Feasibility Study of a Weight-Neutral Health Intervention Active, not recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Active, not recruiting
South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease Recruiting
Investigating Muscle Failure in Diabetic Myopathy Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07010432 on ClinicalTrials.gov ↗ ← All trials in Denmark